Study of alisertib and paclitaxel for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, alisertib and paclitaxel, for people with small cell lung cancer (SCLC) who have already had at least one type of platinum chemotherapy and an immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with small cell lung cancer (SCLC)
- You have already had at least one platinum-based chemotherapy and one immunotherapy (like a PD-1 or PD-L1 inhibitor)
- You may have had up to one additional cancer treatment, for a total of no more than two prior treatments
- Your cancer can be measured on scans (has at least one tumor that can be seen and tracked)
- You have not been treated before with a drug like alisertib that targets aurora kinase A
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial tests a new drug called alisertib for people with small cell lung cancer that has spread. It is for those who have already tried standard treatments (chemotherapy and immunotherapy) and need another option.
This trial tests a combination of two drugs, sacituzumab tirumotecan and anlotinib, for people with extensive-stage small cell lung cancer that has worsened after at least two cycles of standard chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a chemotherapy drug (nab-paclitaxel) combined with local treatments like radiation for small cell lung cancer that has come back after previous treatment. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Hear when a new Small Cell Lung Cancer ( SCLC ) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.